GHENT, BELGIUM--(Marketwire - February 05, 2008) - Ablynx [Euronext Brussels: ABLX], a pioneer in the discovery and development of Nanobodies®, a novel class of antibody-derived therapeutic proteins, announced today that it has been informed that Domantis Limited has filed a Request for Arbitration against Ablynx claiming a dispute exists in relation to the interpretation of certain provisions of a settlement agreement which Ablynx and Domantis entered into on 3 June 2005. In its arbitration claim, Domantis asserts that certain of Ablynx’s activities are not permitted by the terms of the settlement agreement. Domantis claims that it will seek, amongst other things, damages and an order to prevent Ablynx from engaging in these activities in the future.
